Background Clinically significant nonmetastatic prostate cancer (PCa) is currently treated
using whole-gland therapy. This approach is effective but can have urinary, sexual, and rectal …

Importance Screening for prostate cancer using prostate-specific antigen (PSA) testing can
lead to problems of underdiagnosis and overdiagnosis. Short, noncontrast magnetic …

Objective To report medium‐term oncological outcomes in men receiving primary focal
treatment with high‐intensity focused ultrasonography ( HIFU ) for prostate cancer ( PC a). …

Background Focal cryotherapy can be used to treat patients with clinically significant
nonmetastatic prostate cancer to reduce side effects. Objective Early-medium-term cancer control …

Background Focal therapy aims to treat areas of cancer to confer oncological control whilst
reducing treatment-related functional detriment. Objective To report oncological outcomes …

Purpose The trajectory of mechanically ventilated patients with coronavirus disease 2019 (COVID-19)
is essential for clinical decisions, yet the focus so far has been on admission …

Objective To compare the clinical validity and utility of Likert assessment and the Prostate
Imaging Reporting and Data System (PI‐RADS) v2 in the detection of clinically significant and …

Introduction Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole
gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods …

Purpose: We compared clinically significant prostate cancer detection by visual estimation
and image fusion targeted transperineal prostate biopsy. Materials and Methods: This …

Purpose: We determined whether prostate specific antigen criteria after focal high intensity
focused ultrasound to treat prostate cancer could diagnose treatment failure. Materials and …